SK-216, an inhibitor of plasminogen activator inhibitor-1, limits tumor progression and angiogenesis

Molecular Cancer Therapeutics

Volumn 12, Issue 11, 2013, Pages 2378-2388

  Masuda, Takeshi ^a   Hattori, Noboru ^b   Senoo, Tadashi ^b   Akita, Shin ^a   Ishikawa, Nobuhisa ^b   Fujitaka, Kazunori ^b   Haruta, Yoshinori ^b   Murai, Hiroshi ^b   Kohno, Nobuoki ^b  

^a HIROSHIMA UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PLASMINOGEN ACTIVATOR INHIBITOR 1; SHORT HAIRPIN RNA; SK 216; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL MIGRATION; CONTROLLED STUDY; DRUG INHIBITION; EMBRYO; GENE SILENCING; HOST; HUMAN; HUMAN CELL; IN VITRO STUDY; LEWIS CARCINOMA; MELANOMA CELL; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; UMBILICAL VEIN ENDOTHELIAL CELL; WILD TYPE;

ANGIOGENESIS INHIBITORS; ANIMALS; BENZOXAZOLES; CARCINOMA, LEWIS LUNG; CELL LINE, TUMOR; DICARBOXYLIC ACIDS; DISEASE PROGRESSION; GENE KNOCKDOWN TECHNIQUES; HEK293 CELLS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; PLASMINOGEN ACTIVATOR INHIBITOR 1;

EID: 84887488313     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Rakic JM, Maillard C, Jost M, Bajou K, Masson V, Devy L, et al. Role of plasminogen activator-plasmin system in tumor angiogenesis. Cell Mol Life Sci 2003;60:463-73.
2. Smith HW, Marshall CJ. Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol 2010;11:23-36.
3. Stefansson S, Petitclerc E, Wong MK, McMahon GA, Brooks PC, Lawrence DA. Inhibition of angiogenesis in vivo by plasminogen activator inhibitor-1. J Biol Chem 2001;276:8135-41.
4. Konecny G, Untch M, Pihan A, Kimmig R, Gropp M, Stieber P, et al. Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer. Clin Cancer Res 2001;7:1743-9.
5. Heiss MM, Allgayer H, Gruetzner KU, Babic R, Jauch KW, Schildberg FW. Clinical value of extended biologic staging by bone marrow micrometastases and tumor-associated proteases in gastric cancer. Ann Surg 1997;226:736-44
6. Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer MD, et al. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res 2000;60:636-43.
7. Sakakibara T, Hibi K, Kodera Y, Ito K, Akiyama S, Nakao A. Plasminogen activator inhibitor-1 as a potential marker for the malignancy of esophageal squamous cell carcinoma. Clin Cancer Res 2004;10: 1375-8.
8. Muracciole X, Romain S, Dufour H, Palmari J, Chinot O, Ouafik L, et al. PAI-1 and EGFR expression in adult glioma tumors: toward a molecular prognostic classification. Int J Radiat Oncol Biol Phys 2002;52: 592-8.
9. Ohba K, Miyata Y, Kanda S, Koga S, Hayashi T, Kanetake H. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis. J Urol 2005;174:461-5.
10. Werle B, Kotzsch M, Lah TT, Kos J, Gabrijelcic-Geiger D, Spiess E, et al. Cathepsin B, plasminogenactivator-inhibitor (PAI-1) and plasminogen activator-receptor (uPAR) are prognostic factors for patients with non-small cell lung cancer. Anticancer Res 2004;24:4147-61.
11. Bajou K, Noel A, Gerard RD, Masson V, Brunner N, Holst-Hansen C, et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med 1998;4:923-8.
12. Gutierrez LS, Schulman A, Brito-Robinson T, Noria F, Ploplis VA, Castellino FJ. Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1. Cancer Res 2000;60:5839-47.
13. Bajou K, Maillard C, Jost M, Lijnen RH, Gils A, Declerck P, et al. Hostderived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth. Oncogene 2004;23:6986-90.
14. Maillard C, Jost M, Romer MU, Brunnery N, Houard X, Lejeune A, et al. Host plasminogen activator inhibitor-1 promotes human skin carcinoma progression in a stage-dependent manner. Neoplasia 2005;7:57-66.
15. Bajou K, Masson V, Gerard RD, Schmitt PM, Albert V, Praus M, et al. The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies. J Cell Biol 2001;152:777-84.
16. Devy L, Blacher S, Grignet-Debrus C, Bajou K, Masson V, Gerard RD, et al. The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent. FASEB J 2002;16:147-54.
17. Waltz DA, Natkin LR, Fujita RM, Wei Y, Chapman HA. Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. J Clin Invest 1997;100:58-67.
18. Loskutoff DJ, Curriden SA, Hu G, Deng G. Regulation of cell adhesion by PAI-1. APMIS 1999;107:54-61.
19. Bajou K, Peng H, Laug WE, Maillard C, Noel A, Foidart JM, et al. Plasminogen activator inhibitor-1 protects endothelial cells from FasLmediated apoptosis. Cancer Cell 2008;14:324-34.
20. Romer MU, Larsen L, Offenberg H, Brunner N, Lademann UA. Plasminogen activator inhibitor 1 protects fibrosarcoma cells from etoposide- induced apoptosis through activation of the PI3K/Akt cell survival pathway. Neoplasia 2008;10:1083-91.
21. Kwaan HC, Wang J, Svoboda K, Declerck PJ. Plasminogen activator inhibitor 1may promote tumour growth through inhibition of apoptosis. Br J Cancer 2000;82:1702-8.
22. Nishioka N, Matsuoka T, Yashiro M, Hirakawa K, Olden K, Roberts JD. Plasminogen activator inhibitor 1 RNAi suppresses gastric cancer metastasis in vivo. Cancer Sci 2012;103:228-32.
23. Fang H, Placencio VR, Declerck YA. Protumorigenic activity of plasminogen activator inhibitor-1 through an antiapoptotic function. J Natl Cancer Inst 2012;104:1470-84.
24. Charlton PA, Faint RW, Bent F, Bryans J, Chicarelli-Robinson I, Mackie I, et al. Evaluation of a low molecular weight modulator of human plasminogen activator inhibitor-1 activity. Thromb Haemost 1996;75: 808-15.
25. Worzalla JF, Bewley JR, Grindey GB. Automated measurement of transplantable solid tumors using digital electronic calipers interfaced to a microcomputer. Invest New Drugs 1990;8:241-51.
26. Mutoh M, Niho N, Komiya M, Takahashi M, Ohtsubo R, Nakatogawa K, et al. Plasminogen activator inhibitor-1 (Pai-1) blockers suppress intestinal polyp formation in Min mice. Carcinogenesis 2008;29: 824-9.
27. Eitzman DT, Krauss JC, Shen T, Cui J, Ginsburg . Lack of plasminogen activator inhibitor-1 effect in a transgenic mouse model of metastatic melanoma. Blood 1996;87:4718-22.
28. Olofsson B, Korpelainen E, Pepper MS, Mandriota SJ, Aase K, Kumar V, et al. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc Natl Acad Sci U S A 1998;95:11709-14
29. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010;140:883-99.
30. Nakagawa H, Liyanarachchi S, Davuluri RV, Auer H, MartinEWJr, de la Chapelle A, et al. Role of cancer-associated stromal fibroblasts in metastatic colon cancer to the liver and their expression profiles. Oncogene 2004;23:7366-77.
31. Sawdey M, Podor TJ, Loskutoff DJ. Regulation of type 1 plasminogen activator inhibitor gene expression in cultured bovine aortic endothelial cells. Induction by transforming growth factor-beta, lipopolysaccharide, and tumor necrosis factor-alpha. J Biol Chem 1989;264:10396-401.
32. Seki T, Healy AM, Fletcher DS, Noguchi T, Gelehrter TD. IL-1beta mediates induction of hepatic type 1 plasminogen activator inhibitor in response to local tissue injury. Am J Physiol 1999;277:801-9.
33. Loskutoff DJ, Samad F. The adipocyte and hemostatic balance inobesity: studies of PAI-1. Arterioscler Thromb Vasc Biol 1998;18: 1-6.
34. Chapman HA, Yang XL, Sailor LZ, Sugarbaker DJ. Developmental expression of plasminogen activator inhibitor type 1 by human alveolar macrophages. Possible role in lung injury. J Immunol 1990; 145:3398-405.
35. Lund LR, Riccio A, Andreasen PA, Nielsen LS, Kristensen P, Laiho M, et al. Transforming growth factor-beta is a strong and fast acting positive regulator of the level of type-1 plasminogen activator inhibitor mRNA in WI-38 human lung fibroblasts. EMBO J 1987;6: 1281-6.
36. Samad F, Bergtrom G, Amrani DL. Regulation of plasminogen activation by interleukin-6 in human lung fibroblasts. Biochim Biophys Acta 1994;1221:307-14.
37. Ho CH, Chao Y, Lee SD, Chau WK, Wu CW, Liu SM. Diagnostic and prognostic values of plasma levels of fibrinolytic markers in gastric cancer. Thromb Res 1998;91:23-7.
38. Ho CH, Yuan CC, Liu SM. Diagnostic and prognostic values of plasma levels of fibrinolytic markers in ovarian cancer. Gynecol Oncol 1999;75:397-400.
39. Sciacca FL, Ciusani E, Silvani A, Corsini E, Frigerio S, Pogliani S, et al. Genetic and plasma markers of venous thromboembolism in patients with high grade glioma. Clin Cancer Res 2004;10:1312-7.
40. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4-6.
41. Erber R, Thurnher A, Katsen AD, Groth G, Kerger H, Hammes HP, et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 2004;18:338-40.
42. Compagni A, Wilgenbus P, Impagnatiello MA, Cotten M, Christofori G. Fibroblast growth factors are required for efficient tumor angiogenesis. Cancer Res 2000;60:7163-9.
43. Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999;284:1994-8.
44. Kerbel RS. Tumor angiogenesis. N Engl J Med 2008;358:2039-49.